Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Harvard Business School
Baxter
Dow
McKesson

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Patent: 8,715,664

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,715,664
Title:Use of human TNF.alpha. antibodies for treatment of erosive polyarthritis
Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s): Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Wilmette, IL)
Assignee: AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:11/435,844
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,715,664
Patent Claims:see list of patent claims

Details for Patent 8,715,664

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 2002-12-31 ⤷  Try it Free 2039-03-29
Abbvie Inc. HUMIRA adalimumab Injection 125057 2008-02-21 ⤷  Try it Free 2039-03-29
Abbvie Inc. HUMIRA adalimumab Injection 125057 2013-04-24 ⤷  Try it Free 2039-03-29
Abbvie Inc. HUMIRA adalimumab Injection 125057 2014-09-23 ⤷  Try it Free 2039-03-29
Abbvie Inc. HUMIRA adalimumab Injection 125057 2015-11-23 ⤷  Try it Free 2039-03-29
Abbvie Inc. HUMIRA adalimumab Injection 125057 2016-03-09 ⤷  Try it Free 2039-03-29
Abbvie Inc. HUMIRA adalimumab Injection 125057 2016-10-17 ⤷  Try it Free 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
McKesson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.